Johnson & Johnson vs Sanofi, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where JNJ and SNY diverge most: on debt / equity, JNJ reads 0.58 and SNY reads 0.00; on ev/ebitda, JNJ reads 326.4 and SNY reads 14.0. The rest of the comparable metrics sit closer together. What JNJ's price implies is a demanding bet versus history and the cohort (segment-resolved basis). What SNY's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | JNJ | SNY |
|---|---|---|
| Price | $256.46 | $43.08 |
| Market cap | $625.8B | $105.1B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | — | -2.6% |
| P/E | 29.8 | 12.4 |
| P/B | 7.36 | 1.35 |
| P/S | 6.39 | 2.22 |
| EV/EBITDA | 326.4 | 14.0 |
| Revenue growth | +8.1% | +3.7% |
| Gross margin | 68.2% | 77.2% |
| Operating margin | — | 14.5% |
| Net margin | 21.5% | 18.0% |
| Return on equity | 24.8% | 10.9% |
| Return on assets | 10.5% | 6.2% |
| Return on invested capital | — | 7.0% |
| FCF yield | 3.5% | 11.1% |
| Dividend yield | 2.0% | — |
| Debt / equity | 0.58 | 0.00 |
| Current ratio | 1.09 | 1.09 |
| Altman Z (solvency) | 4.95 | 6.53 |
| Piotroski F (quality) | 8 / 9 | 8 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.